Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2024-11-18 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
第四届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting, specifically the fourth board meeting of the fourth session. It details decisions about stock repurchase and lifting restrictions on restricted stock under an incentive plan. The document includes voting results and references to related announcements on the regulatory website. It does not contain financial statements, audit information, or detailed financial data. It is not a full annual or interim report, nor a call transcript or earnings release. It is not a proxy solicitation or dividend notice. The content focuses on board decisions and approvals, which fits the category of Board/Management Information (MANG). The document length is short (1122 characters), and it is a direct announcement of board resolutions, not a report publication announcement or certification. Therefore, the best classification is MANG with high confidence.
2024-11-18 Chinese
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement about obtaining an invention patent certificate issued by the Chinese National Intellectual Property Administration. It includes details about the patent, its application date, authorization date, patent number, and patent type. The document states the patent is for the company's own research and its impact on business operations. There is no financial data, no mention of financial results, no regulatory certifications, or meeting materials. It is a regulatory announcement about intellectual property rights, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive information about the patent. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2024-11-18 Chinese
关于回购注销部分限制性股票减资通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Xiamen Aide Biomedical Technology Co., Ltd. regarding the repurchase and cancellation of part of restricted stock under the 2023 restricted stock incentive plan, which results in a reduction of registered capital. It also notifies creditors about the debt declaration process related to this capital reduction. The document is an official notice to creditors about the company's capital change due to stock repurchase and cancellation, including instructions for debt claims. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a formal announcement related to capital structure changes and creditor notification, fitting the category of Share Issue/Capital Change announcements.
2024-11-18 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于公司2023年限制性股票激励计划首次授予第一个解除限售期解除限售条件成就相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2023 Restricted Stock Incentive Plan of Xiamen Aide Biomedical Technology Co., Ltd. It discusses the achievement of the first unlocking period conditions for the restricted stock incentive plan, approvals, adjustments, and related financial and procedural details. The document is a detailed advisory report on a specific equity incentive plan event, not a general annual or quarterly financial report, nor a simple announcement. It is not a certification or a brief announcement but a substantive advisory report. This fits best under the category of Capital/Financing Update (CAP), as it relates to equity incentive plans and stock-related financing matters.
2024-11-18 Chinese
关于回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a company regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, total amount spent, compliance with regulatory guidelines, and future plans for the buyback. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The content clearly fits the category of a company reporting on its own share transactions (buyback). Therefore, the document is best classified as a Transaction in Own Shares (POS) filing.
2024-11-04 Chinese
关于公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate issued by a national regulatory authority. It details the product name, registration classification, certificate number, validity period, intended use, and the impact on the company. The document is short (779 characters) and serves as a formal notification to investors about a regulatory approval event, not a financial report or detailed management discussion. There is no financial data, earnings information, or detailed report content. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-10-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.